In a report issued on June 12, Phil Nadeau from Cowen & Co. maintained a Hold rating on PDL BioPharma (NASDAQ: PDLI), with a price target of $2.50. The company’s shares closed yesterday at $2.70.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.7% and a 55.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
PDL BioPharma has an analyst consensus of Hold, with a price target consensus of $2.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.55 and a one-year low of $2.15. Currently, PDL BioPharma has an average volume of 1.56M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices.
